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IMPORTANCE: The majority of literature related to disparities in human papillomavirus 
(HPV) vaccination has been focused on sociodemographic differences in vaccine uptake. Now 
nearly ten years after the introduction of the vaccine, and with a better understanding of 
disparities in uptake, a small but growing body of evidence is beginning to examine the impacts 
of the vaccination campaign. Monitoring disparities in the impact of the vaccine is crucial in 
order to better understand the full implications of the vaccine and to properly guide future 
programs and recommendations. 
 
OBJECTIVE: To systematically review the literature on the impact of the human 
papillomavirus vaccine on HPV-related outcomes, and to assess the potential differences in 
impact by various sociodemographic characteristics. 
 
EVIDENCE REVIEW: We systematically searched the global literature using keyword 
searches of the Medline, PubMed, and Web of Science databases between January 1, 2007 and 
January 31st, 2016 to identify studies that met our inclusion criteria. Using a standardized 
protocol, two investigators independently abstracted information on relevant study characteristics 
including principle outcomes, methods, sociodemographic characteristics of the study 
population, and the statistical methods used by the authors to account for these factors. The 
quality of studies (potential for bias and confounding) was assessed by review of participant 
selection or recruitment procedures, and potential confounders considered in the statistical 
analyses. A total of 3,713 records were screened and 45 published studies were included. Results 
were summarized by method of statistical analysis. 
 
FINDINGS: Of the 45 included articles, 22 articles did not collect information on 
sociodemographic variables and 23 collected at least one sociodemographic variable. Variables 
collected varied between studies and countries with the most commonly assessed being race, 
ethnicity, education, urbanization and geographic region of residence. Of the studies that 
collected sociodemographic information, the statistical methods used to account for these factors 
included adjusting (n=15), stratifying (n=5), stratifying and then adjusting (n=1), or no further 
analysis (n=2). Two of the stratified analyses found differences in outcome measures based on 
sociodemographic characteristics such as ethnicity, screening venue, poverty, and urban versus 
nonurban residence. Findings indicated that HPV 16/18 prevalence decreased across all 
screening venues and that there was a significant decrease among white women but the decrease 
among black women was less marked and not significant. Further, there was a strong and 
significant decline in CIN2+/AIS among census tracts that had a lower proportion of the 
population living in poverty, in nonurban counties, and of Black and Hispanic race/ethnicity. The 
remaining three studies that used a stratified analysis found no differences in the outcome 
measures. 
 
CONCLUSION AND RELEVANCE: In order to gain a better understanding of the impact of 
the HPV vaccine on related outcomes, efforts should be made to conduct stratified analyses 
whenever sociodemographic information is available. Further, this review indicates that a higher 
overall uptake of the vaccine may reduce potential disparities in impact and therefore future 




Human papillomavirus (HPV) is the most common sexually transmitted infection in the United 
States with about 79 million Americans currently infected and nearly 14 million new infections 
each year [1]. It is estimated that up to 80% of individuals will acquire HPV at some point in their 
lifetime with about 50% of people acquiring it from their first sexual partner[2]. It has been 
recognized that HPV is a necessary cause of cervical cancer and while many infections are 
asymptomatic, persistent infection may result in outcomes such as genital warts and several 
cancers including cervical, anal, vaginal, vulvar, penile, and oropharyngeal [2]. There are more 
than 50 anogenital types of HPV and of those, 18 are considered to be high-risk due to their 
strong association with cervical cancer [3].  
 
Since 2006, the United States Food a Drug Administration (FDA) has approved three vaccines 
that protect against HPV-16 and HPV-18, which are known to cause 70% of invasive cervical 
cancers [3]. The bivalent HPV2 vaccine (Cervarix) prevents infection with HPV 16/18 and the 
quadrivalent HPV4 vaccine (Gardasil) provides additional protection against HPV-6 and HPV-
11 [4]. In December 2014, the FDA approved a 9-valent vaccine (Gardasil 9) that protects against 
HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 [4]. Current recommendations from the Advisory 
Committee on Immunization Practices (ACIP) are for routine vaccination for adolescent females 
and males aged 11 or 12, and a catch-up period for those not previously vaccinated through the 
age of 21 for males and age 26 for females [5].  
 
Thus far, the majority of literature related to disparities in HPV vaccination has been focused on 
sociodemographic differences in vaccine uptake. Current trends in the U.S. indicate that 
initiation of the HPV vaccine is highest among Hispanic adolescents, followed by black 
adolescents, with white adolescents having the lowest vaccine uptake overall [6]. In addition, by 
2011 Hispanic adolescents had the highest percentage of initial vaccine coverage as well as the 
greatest increase in vaccine coverage since the introduction of the vaccine [6]. However, 
compared to Hispanic and non-Hispanic white females, black females had a lower rate of 
vaccine series completion [7]. In looking at vaccine uptake by poverty status, a 2014 CDC report 
showed that vaccine series initiation among girls living below the national poverty line was 
higher than that of girls living above the poverty line [7]. Nonetheless, the rate of series 
completion is lower among adolescents below poverty than for those living above poverty [8]. 
Finally, Mehta et al. described in 2012 how publicly insured (77%) and uninsured (85%) women 
were more likely than privately insured women (48%) to report no history of vaccination [9].  
 
Now nearly ten years after the introduction of the first vaccines for HPV, a small but growing 
body of evidence is beginning to examine the impacts of the vaccination campaign. The purpose 
of this article is to systematically review the literature on the impact of the human papillomavirus 
vaccine on HPV-related outcomes, and to assess the potential differences in impact by various 
sociodemographic characteristics. Results can be used to identify potential disparities and areas 








This systematic review is registered in PROSPERO (registration number is CRD42016036465), 
an international database of prospectively registered systematic reviews in health and social care 
[10]. The review protocol is available on the Centre for Reviews and Dissemination website. 
 
We systematically reviewed the global literature and report it according to the PRISMA 
guidelines [11].  Our primary search was conducted in the MEDLINE database with a 
combination of the following Medical Subject Heading (MeSH) terms, title, or abstract words: 
(“papillomavirus infections”, or “uterine cervical dysplasia”, or “adenocarcinoma in situ”, or  
“cervical intraepithelial neoplasia”, or (“cervical or cervix” adj “dysplasia or neoplasia or 
lesion”)) and (“papillomavirus vaccines”, or “HPV vaccine”, or “human papillomavirus 
vaccine”, or “HPV vaccination”, or “human papillomavirus vaccination”). In addition to using 
the search terms to identify additional eligible articles in the PubMed database, we also 
conducted a cited reference search in Web of Science and searched the references of eligible 
articles. Databases were searched for relevant articles published from January 1, 2007 through 
January 31st, 2016. In order to identify eligible articles, the inclusion criteria below were applied 
first to the titles and abstracts of articles and then to full-text articles in order to determine final 
inclusion status. Conference abstracts were excluded from this review.  
 
The primary inclusion criteria was that articles had to report data about vaccine impact using at 
least one primary endpoint including anogenital warts, histopathologically confirmed high-grade 
cervical lesions (cervical intraepithelial neoplasia [CIN] 2 or higher), or HPV infection. Studies 
were excluded for the following reasons: (1) not a source of primary data (news articles, 
recommendations, editorials, etc.), (2) no trends or data from a pre- and post-vaccine era, (3) 
randomized control trials of vaccine efficacy, and (4) duplicate articles. If more than one 
exclusion criteria applied, only the first criteria was listed as dictated by the numerical order 
above. Further, if more than one publication from the same data source and research team was 
available, we included both articles as analyses may have changed over time.  
 
A standardized form was created to extract the relevant study characteristics for all included 
studies. For each study, we collected information about country or region of study, study 
population, setting, principle outcomes, methods, and if applicable, whether or not the authors 
collected information of sociodemographic characteristics, reported sociodemographic 
characteristics of the study population, and how the authors accounted for these factors. Two 
authors reviewed each article independently and discrepancies were resolved through discussion 
in order to achieve consensus regarding the accuracy of data extraction. The quality of studies 
(potential for bias and confounding) was assessed by review of participant selection or 
recruitment procedures, and potential confounders considered in the statistical analyses. No 
formal meta-analysis was performed due to a small number of eligible studies that could be 









In our search, we identified 3,713 abstracts, of which 45 met our inclusion criteria[12-56] (Figure 
1) and all of the included studies had sufficient methodological quality to be qualitatively 
described (Appendix A). Characteristics of the included studies are summarized in Table 1. 
Studies were done in 11 high-income countries including Australia, New Zealand, the United 
States, Sweden, Denmark, England, Germany, Scotland, Belgium, the Netherlands and Canada. 
The endpoints varied widely in each study but included prevalent HPV infections (n=3), type 
specific infections (including vaccine-type specific) (n=7), high-grade cervical abnormalities 
(CIN2+/AIS) (n=5), genital warts (n=25), atypia or worse (n=2), cervical abnormalities (n=1), 
incident abnormal events (CIN 1-3) (n=1), and general cervical cytology and histology results 
(n=1). Of the 45 included articles, 22 articles did not collect information on sociodemographic 
variables and 23 collected at least one sociodemographic variable. Variables collected varied 
between studies and countries with the most commonly assessed being race, ethnicity, education, 
urbanization and geographic region of residence. Of the studies that collected sociodemographic 
information, the statistical methods used to account for these factors included adjusting (n=15), 
stratifying (n=5), stratifying and then adjusting (n=1), or no further analysis (n=2).  
 
Adjusted Analyses 
In total, 15 studies used adjusted analyses when presenting findings on their primary outcomes. 
Among these studies, 8 papers presented both crude and adjusted measures[19,25,27,34,38,42,48,51,55] 
while the remaining 7 papers presented only the adjusted estimates. Within the 8 studies that 
presented crude and adjusted data, 4 studies made some indication that there was little to no 
difference between the two estimates and therefore the potential for confounding was 
unlikely[19,25,51,55]. In addition, there was usually a limited discussion, if any, about the role of 
potential confounders. Where a discussion was presented, it was a more general discussion about 
confounding and was not specific to sociodemographic factors.  
 
Stratified Analyses 
There were 5 studies that presented stratified analyses[40,43,47,52,53] and 1 study that first stratified 
and then adjusted in the absence of effect modification[29]. Sociodemographic factors collected 
and used in the stratified analysis varied and included some regionally specific characteristics.  
 
Two of the five stratified studies found differences in outcome measures based on the variables 
used in the analyses. One study from England assessed the prevalence of vaccine-type HPV 
infections and stratified the analysis based on the screening venue (general practice, youth clinic, 
or family planning Community Sexual Health Services) and ethnicity[40]. When looking at the 
prevalence of type 16/18 infection by ethnicity, the authors reported that from the pre-
immunization to the post-immunization period, there was a significant decrease in prevalence 
among white women (19.7% to 6.7%) but the decrease among black women was less marked 
and not significant (14.9% to 9.4%)[40]. Further, they reported a reduction in the prevalence of 
HPV 16/18 among 16-18 year olds of 76% in the GP clinics, 64% in community sexual health 
services centers, and 55% in youth clinics from the pre- to the post-immunization periods[40]. The 
significance of this finding was not reported. The second paper was a 2013 paper from the 
United States that assessed CIN2+/AIS trends over time in Connecticut[43]. The analysis was 
stratified by ethnicity (proportion of black and Hispanic), poverty as defined by the percentage of 
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population in each census tract living below the federal poverty level, and urban versus nonurban 
residence[43]. The main finding from the stratified analysis was that there was a strong and 
significant decline in census tracts that had a lower proportion of the population living in 
poverty, in nonurban counties, and of Black and Hispanic race/ethnicity[43]. The authors discuss 
that the reason for this disparity is not clear but may reflect a higher prevalence of vaccine-type 
strains (HPV 16/18) among White women and women living in low poverty areas[43]. 
 
The remaining three studies that used a stratified analysis found no differences in the outcome 
measures based on the various sociodemographic factors that they considered. Two studies from 
Australia looked at trends in genital warts in years pre- and post-vaccine[52,53]. The first study 
conducted a stratified analysis by indigenous status and concluded that the fall in genital warts 
admissions in young females (15-24) after implementation of the National HPV Vaccination 
Program (NHVP) was comparable for indigenous and non-indigenous females[52]. The second 
study stratified by two variables including residency inside or outside of a major city and an 
Index of Relative Socioeconomic Disadvantage (IRSD)[53]. IRSD is a measure that uses 
characteristics such as income, unemployment, occupation skill level and housing to create a 
score that is then placed into a ranking[53]. The authors found that there were no significant 
differences in the estimated reductions between women living in more versus less disadvantaged 
areas and that the reduction in genital warts admissions among young men were similar for those 
residing in and outside of major cities[53]. Finally, a study from Boston, USA also looked at 
trends in genital warts and concluded from their stratified analysis that there were significant 
declines in the rate of genital warts following the introduction of the vaccine and that the 
declines warts were similar for males and females of all race/ethnicities[47].  
 
Other Analyses  
Finally, 2 articles collected sociodemographic characteristics of race/ethnicity[24,31] and 
insurance[31] but only used the data for descriptive purposes and did not further account for them 




The current body of literature surrounding uptake of the HPV vaccine in the United States 
suggests that there are potential disparities in who is initiating and completing the vaccine series. 
With this kind of evidence at hand, it is important to consider that there may be disparities in the 
impact of the vaccine. This review of 45 studies revealed that approximately half of the studies 
collected information related to sociodemographic characteristics of the study population and of 
those, yet only 5 studies conducted a stratified analysis in order to examine the potential role of 
these factors on their outcomes of interest. While reporting sociodemographic characteristics of 
the study population provides some insight, an adjusted statistical analysis takes away the ability 
to determine the role that a secondary factor may have on the outcome of interest. A stratified 
analysis is almost always useful and allows researchers to learn more about the complex 
relationships between variables of interest. Further, this approach provides a better understanding 
of the potential strength of an association in various strata of the potentially confounding variable 
rather than from a single estimate, such as in an adjusted analysis.  It is our recommendation that 
when sociodemographic information is available, stratified analyses should be considered in 
order to gain a better understanding of the impact that the vaccine may be having on different 
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populations. Further, an analysis that both stratifies and then controls for additional 
characteristics may provide the most information and allow researchers to focus solely on one 
variable at a time, although these kinds of analyses were not seen in this body of literature.  
 
There are a number of reasons why more research has not been done in this area regarding 
disparities in the HPV vaccine impact. First, the relevant data may not be available to do a 
stratified analysis. Many of the large-scale surveillance studies used population level data or 
extracted data from claims forms and medical chart reviews. In this situation, it may be more 
difficult to link sociodemographic characteristics to the population compared to a study where 
participants are enrolled, followed prospectively, and actively participate in providing 
information to the researchers. Next, it may be important to consider the baseline vaccine uptake 
in a population in order to gauge if disparities in the outcomes are likely to occur. For example, 
in the United States, coverage with at least one dose of the vaccine was at 60.0% in 2014 but 
complete coverage with the 3-dose series remained low at 39.7%[57]. In contrast, in 2014 it was 
estimated that 88.1% of females in grade 9 in England[58] and between 70.1% to 75.6% of 
females in Australia had completed the HPV vaccine series[53]. With these differences in mind, it 
may make sense that a stratified analysis from the U.S. demonstrated differences in the decline 
of CIN2+/AIS by measures of race/ethnicity, poverty, and area of residence[43], while in the two 
stratified analyses from Australia, there were no differences in the outcome for different 
populations[52,53]. This may suggest that in a population where vaccine uptake is low, the 
potential for disparities is higher than in a population with more widespread coverage. However, 
this suggestion does not hold true for all the stratified analyses presented here and thus continued 
surveillance is needed in order to better understand the role of vaccine uptake on disparities in 
HPV-related outcomes. 
 
In addition to differences in vaccine uptake, it is important to consider other factors that may 
contribute to disparities in vaccine impact. Most notably, Hariri et al. described differences in 
HPV type distribution by a number of sociodemographic variables. The main finding from this 
study was that cervical lesions associated with HPV types 16/18 were less common in non-
Hispanic blacks (41.9%), and Hispanics (46.3%) compared to non-Hispanic whites (59.1%) and 
these differences were statistically significant[59]. Further, Niccolai et al. added in 2013 that in 
addition to black race and Hispanic ethnicity, higher area-based poverty was a salient predictor 
of lower HPV 16/18 positivity among women who were diagnosed with high-grade cervical 
lesions[60]. Together, these findings suggest that current HPV vaccines may have a lower impact 
on particular populations thus further perpetuating disparities that may already exist. Second-
generation vaccines, such as the 9-valent vaccine, may provide additional benefit for some 





This systematic review does have some limitations that need to be acknowledged. The existing 
published studies did not allow for a quantitative meta-analysis and to be as comprehensive as 
possible and aid in the wide dissemination of findings, we did not exclude any study on the basis 
of quality. However, based on our quality review of the included studies, no studies fell into a 
low quality range and should all, therefore, provide robust and unique evidence to our potential 
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understanding of HPV vaccine impact. In addition, there is always a conceivable risk of 
publication bias in a review of this nature due to the inclusion of only peer-reviewed, full-text 
articles. Finally, the studies included in this review were all from high-income countries and 
therefore the conclusions made cannot be further generalized to other middle- or low-income 
countries, as we do not currently have a strong understanding of the HPV vaccine landscape in 




This review provides a systematic and comprehensive summary of the impacts of the HPV 
vaccine on HPV-related outcomes and the potential disparities in those outcomes that have been 
identified in the literature. While the body of literature is growing, continued surveillance is 
needed to measure vaccine impact and monitor health disparities. In order to gain a better 
understanding of the impact of the HPV vaccine on related outcomes, efforts should be made to 
conduct stratified analyses whenever sociodemographic information is available. Further, this 
review indicates that a higher overall uptake of the vaccine may reduce potential disparities in 








































































































































































































































































Figure 1. Flow Diagram (Preferred Reporting Items for Systematic Review and Meta-
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Appendix A: Assessment of Quality and Confounding 
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